Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-escalation, Dose-finding, and Expansion Study of XL495 as a Single Agent and in Combination Therapy in Participants With Locally Advanced or Metastatic Solid Tumors

NCT06630247 is registered in ClinicalTrials.gov with Exelixis as lead sponsor.

NCT NCT06630247
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06630247 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-escalation, Dose-finding, and Expansion Study of XL495 as a Single Agent and in Combination Therapy in Participants With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Exelixis
Phase
Phase 1
Overall status
Terminated
Start date
October 17, 2024
Completion date
May 7, 2025
Enrollment
9 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced solid tumor, metastatic solid tumor, solid cancers, solid tumor cancer, solid tumor malignancy, urothelial cancer (urinary bladder, ureters, or renal pelvis cancer), urothelial cancer of renal pelvis